Claims

1. Use of a pharmaceutical or dermatological composition in the manufacture of a medicament for the treatment of disease and/or pathologies selected from the group comprising fibrosis, retinal detachment, and/or treatment of age-related macular degeneration, dry age-related macular degeneration, wet age-related macular degeneration, ~~tissue dryness, mucous membrane dryness,~~ epidermolysis bullosa, periodontal diseases, diseases of the buccal mucous membrane, burns, degenerative diseases, ~~skin aging~~, lesions of the respiratory system, wherein said pharmaceutical or dermatological composition comprising

- a biocompatible polymer of the general formula (I) below

AaXxYy (I)

in which:

A represents a monomer, which is glucose

X represents an R_1COOR_2 or $–R_9(C=O)R_{10}$ group,

Y represents an O or N-sulfonate group complying with one of the following formulae: $–R_3OSO_3R_4$, $-R_5NSO_3R_6$, $R_7SO_3R_8$ in which:

R_1, R_3, R_5 and R_9 independently represent an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which optionally contains one or more aromatic cycles with the exception of benzylamine and benzylamine sulfonate, R_2, R_4, R_6 and R_8 independently represent a hydrogen atom or a cation,

R_7 and R_{10} independently represent a bond, an aliphatic hydrocarbon chain, optionally branched and/or unsaturated,

a represents the number of monomers,

x represents the rate of substitution of the monomers A by the groups X, y represents the rate of substitution of the monomers A by the groups Y, and

- hyaluronic acid.

2. A method for hydrating tissue and/or mucous membrane, and/or improving aging skin using a dermatological composition, wherein said dermatological composition comprises

- a biocompatible polymer of the general formula (I) below

AaXxYy (I)

in which:

A represents a monomer, which is glucose

X represents an R_1COOR_2 or $–R_9(C=O)R_{10}$ group,

Y represents an O or N-sulfonate group complying with one of the following formulae: $–R_3OSO_3R_4$, $-R_5NSO_3R_6$, $R_7SO_3R_8$ in which:

R_1, R_3, R_5 and R_9 independently represent an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which optionally contains one or more aromatic cycles with the exception of benzylamine and benzylamine sulfonate, R_2, R_4, R_6 and R_8 independently represent a hydrogen atom or a cation,
R_7 and R_{10} independently represent a bond, an aliphatic hydrocarbon chain, optionally branched and/or unsaturated,
a represents the number of monomers,
x represents the rate of substitution of the monomers A by the groups X, y represents the rate of substitution of the monomers A by the groups Y, and
- hyaluronic acid.

3. The method according to claim 2, wherein improving aging skin comprises increase cutaneous hydration, have an anti-wrinkle effect, improve the radiance and brightness of the skin, have uniform complexion, increase in texture, elasticity, coolness and/or tone of the skin.

4~~2~~. The use of claim 1, or the method according to claims 2~~1~~ or 3, wherein the number of monomer “a” is such that the mass of said polymers of formula (I) is greater than or equal to 3000 Daltons.

5~~3~~. The use of claim 1 or 4, or the method according to any one of claims 2 to 4~~ 1 or 2~~, wherein the rate of substitution “x” is between 10 and 150%.

6~~4~~. The use of any one of claims 1, 4 to 5, or the method according to any one of ~~the preceding~~ claims 2 to 5, wherein the rate of substitution “y” is between 10 and 170%.

7~~5~~. The use of any one of claims 1, 4 to 6, or the method according to any one of ~~the preceding~~ claims 2 to 6, characterized in that the radical R is selected from a linear or branched alkyl, allyl or aryl group.

8~~6~~. The use of any one of claims 1, 4 to 7, or the method according to any one of ~~the preceding~~ claims 2 to 7, wherein said biocompatible polymer further comprises chemical functional groups Z which are different from X and Y and are capable of providing said polymer with additional biological or physicochemical properties.

9~~7~~. The use of claim 8, or the method according to claim 8~~6~~, wherein the rate of substitution “z” of all the monomers A, by the groups Z, is between 1 and 50%.

10~~8~~. The use of claims 8 or 9, or the method according to ~~either~~ claim 8~~6~~ or ~~claim~~ 9~~7~~, wherein the group Z is a substance capable of providing said polymers with an improved solubility or lipophilicity.

11~~9~~. The use of claim 10, or the method according to claim 10~~8~~, wherein the groups Z are identical or different and are selected from the group comprising amino acids, fatty acids, fatty alcohols, ceramides, or derivatives thereof, or indeed addressing nucleotide sequences.